Navigation Links
Mayo Clinic research finds risk of glaucoma blindness drops by half
Date:1/22/2014

ROCHESTER, Minn. Jan. 21 A comparative long-range study by Mayo Clinic ophthalmology researchers shows that the probability of blindness from glaucoma 20 years after diagnosis has dropped by half in the last generation. The findings appear online in the "in press" section of the journal Ophthalmology.

The researchers examined the medical records of all residents of Olmsted County, Minnesota, age 40 or above, diagnosed with glaucoma between 1981 and 2000. They compared this with similar data from a previous study of patients diagnosed between 1965 and 1980, using the same resource, the repositories of the Rochester Epidemiology Project.The findings: While the incidence of glaucoma in the population has not changed, the probability of going blind in at least one eye due to glaucoma dropped by half, from 25.8 percent in the earlier study, to 13.5 percent in the later period. As well, the annual incidence of glaucoma-caused blindness in the population has dropped by more than half.

"This is a testament to the skill and effort of the researchers, physicians and other care providers working in eye care over that period," says Arthur Sit, M.D., Mayo Clinic ophthalmologist and senior author of the study. "Our improved understanding of glaucoma, along with better treatment and management of patients seem to have had this impact. Still, much research and public education remains to be performed. A 14 percent blindness rate from a common eye disease is hardly ideal."

Dr. Sit discounted early diagnosis as a factor in the dramatic shift, noting that the age of first diagnosis for glaucoma patients has not changed. The study also has its limitations. While it reflects virtually every case of glaucoma in the study county, the population over the period was roughly 90 percent white and does not necessarily reflect more diverse communities.

There is no early warning sign of glaucoma, other than loss of peripheral vision, which most people fail to notice. Dr. Sit urges regular eye appointments as the best way to diagnose the condition.


'/>"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
2. First targeted nanomedicine to enter human clinical studies
3. Clinical insight improves treatment with new lung cancer drug
4. Clinical news alert from the American Academy of Orthopaedic Surgeons
5. Mayo Clinic launches whole genome breast cancer study
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. NYU Langone experts present research, clinical advances at neurosurgeons meeting
8. Mayo Clinic breast cancer study finds new type of mutation
9. Kroenke honored for outstanding contributions in clinical research training
10. Awards celebrate clinical research that can improve health and alleviate suffering
11. Association for Psychological Science, SAGE launch Clinical Psychological Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a ... Scooters . , Mobility Scooters give freedom to people who need help getting around. ... may be facing a long period of rehabilitation after an illness or accident. There ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a ... lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO of ... create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... GA (PRWEB) , ... December ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education ... Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on ... “We are honored to have Amy E. Herman present at this year’s conference, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Lexicon Pharmaceuticals, ... results today from a Phase 2 clinical study of ... Lexicon in collaboration with JDRF, the leading global organization ... of this Phase 2 clinical trial, which randomized a ... of a once-daily 400 mg dose of sotagliflozin compared ...
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... PORTLAND, Oregon and PUNE, India ... a new report by Allied Market Research, titled, "Global Cancer ... the global revenue of cancer biomarkers market is projected to ... at a CAGR of 13.3% from 2016 to 2022. Omic ... share in 2015 and is expected to maintain its dominance ...
Breaking Medicine Technology: